Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have CLL (confirmed by your doctor) and your disease must be measurable on scans or tests.
- You must be currently taking zanubrutinib (a targeted cancer pill).
- You must have either: some remaining disease (even if on zanubrutinib) OR your CLL has worsened on zanubrutinib and you have no other standard options.
- You cannot have certain high-risk CLL features (like TP53 mutations or 17p deletion) if you are in the first group.
- You must be willing to take oral medications and have a contrast CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, sonrotoclax, and obinutuzumab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a targeted therapy called zanubrutinib for people aged 80 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It may help control the disease with fewer side effects than standard chemotherapy.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and bendamustine) as a first treatment for people with chronic lymphocytic leukemia (CLL) who have not had any previous therapy. The goal is to see if this combination is safe and effective.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.